Aardvark Therapeutics, Inc.
AARD Nasdaq
SEC CIK 1774857
Follow Aardvark Therapeutics
Weekly email: filings, results, news
Revenue, last quarter
$0
Net income
−$14.4M
−0.1% vs same quarter last year
EPS, diluted
−$0.66
+0% vs same quarter last year
Operating cash flow
−$17.6M
−78.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
News
No stories filed under Aardvark Therapeutics yet - coverage appears here as the news feed clusters it.